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a b s t r a c t
An important step in the malignant progression of HPV-associated lesions is the dysregulation of
expression of the viral E6 and E7 oncogenes. This is often achieved through the loss of expression of E2,
which represses the HPV LCR promoter and E6/E7 expression. Our previous studies conﬁrmed a role for
Brd4 in mediating the E2 transcriptional repression function, and identiﬁed JARID1C/SMCX and EP400 as
contributors to E2-mediated repression. Here we show that TIP60, a component of the TIP60/TRRAP
histone acetyltransferase complex, also contributes to the E2 repression function, and we extend our
studies on SMCX. Di- and tri-methyl marks on histone H3K4 are reduced in the presence of E2 and
SMCX, suggesting a mechanism by which SMCX contributes to E2-mediated repression of the HPV LCR.
Together, these ﬁndings lead us to hypothesize that E2 recruits histone-modifying cellular proteins to the
HPV LCR, resulting in transcriptional repression of E6 and E7.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Human papillomaviruses (HPV) infect squamous epithelial cells
and cause a variety of epithelial lesions. ‘High risk’ alpha genus
HPV types infect the mucosal epithelium and are associated with
some cancers, most notably cervical cancer. A growing body of
evidence also links HPV infection to other anogenital cancers and
oropharyngeal cancers (zur Hausen, 2009). The viral E6 and E7
proteins account for the oncogenic potential of high-risk HPVs, in
part through the ability of E6 to bind and degrade the tumor
suppressor p53 and of E7 to bind and inactivate the retinoblas-
toma family of pocket proteins (Howley et al., 2013). Expression
of the viral E6 and E7 genes is controlled through an upstream
promoter and enhancer region referred to as the long control
region (LCR). DNA viruses that usurp host cellular machinery for
their replication, including papillomaviruses, tend to have chro-
matin structures much like cellular chromatin and to retain core
histones when they are packaged into viral particles. Papilloma-
virus DNA is chromatinized much like cellular DNA, and it is
thought to be subject to similar regulation by chromatin modiﬁca-
tions. HPV genes impact chromatin modiﬁcation in a variety of
ways, for example HPV18 E6 protein interacts with and modulates
the function of the histone acetyltransferase p300 (Thomas
and Chiang, 2005) and HPV16 E7 protein has been reported to
interact with the Mi2 ATPase–histone deacetylase complex (Brehm
et al., 1999). In addition E7 induces KDM6A and KDM6B histone
demethylase expression and causes epigenetic reprogramming
(McLaughlin-Drubin et al., 2011).
During the normal course of viral replication, the papilloma-
virus E2 protein regulates E6 and E7 oncogene expression. E2
binding to the four E2 binding sites within HPV LCRs results in
diminished E6 and E7 expression (Bernard et al., 1989; Hwang
et al., 1993; Thierry and Howley, 1991; Thierry and Yaniv, 1987).
This could lead to repression of the HPV LCR in one or more of
several ways. The binding of E2 to its cognate sites in the LCR may
compete with binding of speciﬁc cellular transcription factors
(Dong et al., 1994; Dostatni et al., 1991). Yet, the ﬁnding that single
amino acid substitution mutants of E2 still competent for DNA
binding are deﬁcient in their ability to repress the E6/E7 promoter
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suggests that E2 recruits cellular factors to the LCR to mediate its
repressive function (Dowhanick et al., 1995; Goodwin et al., 1998;
Nishimura et al., 2000).
To identify the cellular proteins and pathways involved in
E2-mediated transcriptional repression of the HPV18 LCR, we
previously conducted a genome-wide siRNA screen (Smith et al.,
2010). Our study conﬁrmed the reported role for the E2-binding
bromodomain protein Brd4 in E2-mediated silencing (Wu et al.,
2006) and identiﬁed a number of genes that had not previously
been implicated in E2 repression (Smith et al., 2010). We validated
that both the demethylase JARID1C/SMCX and EP400, a compo-
nent of the TIP60 histone acetyltransferase complex, contribute to
E2-mediated repression and bind to E2 (Smith et al., 2010). Brd4,
SMCX and EP400 contribute independently and additively to
E2-mediated silencing, indicating that E2 functions through sev-
eral distinct cellular complexes to repress E6 and E7 expression.
SMCX is a demethylase, also referred to as KDM5C or JARID1C.
SMCX speciﬁcally demethylates tri- and di-methylated histone H3
lysine 4 (H3K4) (Iwase et al., 2007). EP400 is a component of the
multi-subunit TIP60 histone acetyltransferase complex (Doyon
and Cote, 2004) that was ﬁrst identiﬁed through its ability to bind
the adenovirus E1A protein (Fuchs et al., 2001). This complex also
has ATP-dependent DNA helicase activities and is involved in
transcriptional activation and repression functions (Ikura et al.,
2000). In addition to EP400, this complex contains the TIP60
protein itself as well as other factors including γ-actin, the actin-
related-protein (ARP) BAF53 and EPC, a human homolog of the
Drosophila Enhancer-of-Polycomb protein. TRRAP, a transcriptional
regulatory protein found in the human STAGA/TFTC and PCAF
complexes, is also a component of the TIP60 complex (Ikura et al.,
2000; Vassilev et al., 1998). EP400 has been implicated in direct
binding to the histone acetyltransferase domain of TIP60, blocking
TIP60's enzymatic activity and its co-activator function in regula-
tion of p21 expression through the SWI3–ADA2–N-CoR–TFIIIB
(SANT) domain of EP400 (Park et al., 2010).
We have continued these studies on E2-mediated transcrip-
tional repression of the HPV18 LCR with the goal of elucidating
the mechanisms by which SMCX and EP400 contribute to its
downregulation. Here we show that E2, together with the cellular
proteins SMCX and the TIP60 complex, contributes to the estab-
lishment of a speciﬁc pattern of chromatin modiﬁcations on and
around the HPV LCR. This leads to repression of the papillomavirus
oncogenes E6 and E7.
Results
Mutational analysis of the E2 transactivation domain in binding
SMCX, Brd4 and EP400
The N-terminal transactivation domain of the papillomavirus
E2 protein plays an essential role in E2-mediated repression due to
its ability to complex with speciﬁc cellular factors such as Brd4
(You et al., 2004). Mutations in the E2 transactivation domain that
obviate its transcriptional activation function affect the ability
of E2 to repress the E6/E7 promoter (Dowhanick et al., 1995;
Goodwin et al., 1998; Nishimura et al., 2000). Single amino acid
substitution mutants of the BPV1 or HPV16 E2 transactivation
domain at amino acids R37 or I73 are defective in binding Brd4
(Baxter and McBride, 2005; Schweiger et al., 2006), and R37 and
I73 are exposed on the same face of the E2 transactivation domain
(Antson et al., 2000; Schweiger et al., 2006). We have previously
shown that both BPV1 E2 and HPV16 E2 coimmunoprecipitate
with SMCX as well as EP400 (Smith et al., 2010).
To determine whether SMCX and/or EP400 also bind to the face of
the E2 transactivation domain containing R37 and I73, we performed
anti-HA immunoprecipitations of HA-tagged BPV1 E2, wild-type (wt)
or alanine substitution mutants, in C33A cells co-transfected with
expression plasmids encoding FLAG-tagged SMCX or EP400. BPV1 E2
was used in these studies because the binding of BPV1 E2 to Brd4,
EP400 and SMCX is more robust and easier to detect (Smith et al.,
2010). Expression plasmids were used to enhance their respective
protein levels in the cells for detection in complex with E2. Cell lysates
were harvested 48 h post-transfection and sonicated to reduce the size
of nucleic acid fragments that might be involved in mediating E2
protein interactions with binding partners. Input and precipitated
proteins were separated by SDS/PAGE and visualized by immunoblot
analysis. Tagged BPV1 E2 (wt) as well as the R37A, I73A and R37A/I73A
double mutants were expressed at comparable levels (Fig. 1A) and
could be efﬁciently immunoprecipitated with the HA antibody
(Fig. 1B). In agreement with previous studies, endogenous Brd4 co-
immunoprecipitated with BPV1 E2 (wt), but not with the R37A, I73A
or R37AI73A mutants (Fig. 1B). SMCX co-immunoprecipitated with wt
E2 as well as the R37A mutant, but co-immunoprecipitation with
either the I73A or R37AI73A mutant was signiﬁcantly reduced. These
results suggest that the ability of SMCX to complex with E2 involves
the same face of the E2 transactivation domain involved in Brd4
binding since the alanine point mutants have at least some effect on
its co-immunoprecipitation with E2. In contrast, EP400 efﬁciently
co-immunoprecipitated with the wt BPV1 E2 as well as each of the
single mutants (R37A and I73A), but to a somewhat lesser extent with
the double mutant R37A/I73A (compare the levels of EP400 in the E2
co-immunoprecipitation lanes with the levels in the input lanes).
Fig. 1. N-terminal amino acids of BPV1 E2 contribute to interactions with Brd4,
SMCX and EP400. C33A cells were transfected with expression plasmids for
HA-tagged wt or mutant (R37A, I73A, R37AI73A) BPV1 E2, FLAG–SMCX, FLAG–
EP400 or the corresponding parental plasmids. 48 h Post-transfection, cells were
harvested and proteins immunoprecipitated with an antibody against HA. Total
cellular proteins (A) and bound proteins (B) were separated by SDS-PAGE and
visualized by immunoblot analysis using antibodies against HA (detection of BPV1
E2), Brd4, SMCX, EP400 and actin.
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Neither BPV1 E2 R37 nor I73 is required for EP400 interaction with
BPV1 E2, although the E2 double mutant is less efﬁcient in binding.
Mapping the regions of EP400 required for complexing with E2
To further characterize the interaction of E2 with EP400, we
mapped the regions of EP400 involved in its ability to co-
immunoprecipitate with E2 using six FLAG-tagged fragments of
EP400 spanning the length of the protein (Park et al., 2010).
A schematic representation of EP400 indicating its domains and the
fragments used is illustrated in Fig. 2A. We validated the expression of
the various FLAG-tagged EP400 fragment constructs (Fig. 2B) and used
them to map the regions of EP400 involved in interacting with the
papillomavirus E2 protein in C33A cells. In subsequent experiments,
EP400 fragment levels were normalized based on the variation in
EP400 fragment expression observed here by adjusting the amount of
EP400 plasmid included in each condition. Fragment F3 was cytotoxic
and could not be expressed at a higher level than shown. C33A
cells were co-transfected with FLAG-tagged EP400 fragments and
HA-tagged BPV1–E2, followed by HA-immunoprecipitation and wes-
tern blotting with anti-HA and FLAG antibodies. Fragments F1, F2 and
F4 of EP400, as well as the smaller SANT domain region of fragment F4
co-immunoprecipitated with E2 (Fig. 2C and D). The regions of EP400
that complex with E2 are the same regions of EP400 that have been
mapped for binding to TIP60 (Park et al., 2010).
E2 interacts with TIP60
The ﬁnding that the regions of EP400 involved in complexing with
E2 were the same as EP400 binding to TIP60, as well as the previous
ﬁnding that other members of the TIP60 complex contributed to
E2-mediated repression of the LCR (Smith et al., 2010), led us to
investigate whether TIP60 is part of the cellular complex engaged by
the papillomavirus E2 protein. We therefore tested whether TIP60 and
BPV1 E2 co-immunoprecipitate. C33A cells were co-transfected with
the dual-tagged FLAG–HA–BPV1 E2 and HA–TIP60. As controls, cells
were co-transfected with either the HA–TIP60 or the FLAG–HA–BPV1
E2 plasmid alone. FLAG-tagged EP400 fragment F4 was used as a
positive control, since it has been documented to bind to TIP60 (Park
et al., 2010). Anti-FLAG beads were used to immunoprecipitate BPV1
E2, and western blot analysis for anti-FLAG revealed efﬁcient immu-
noprecipitation for both FLAG–F4 and FLAG–HA–E2 (Fig. 3A). Anti-HA
immunoblotting revealed that either EP400 F4 or E2 pulled down
HA–TIP60. The interaction between E2 and TIP60 was conﬁrmed in a
second cell line, HeLa cells (Fig. 3B). HeLa is an HPV18 positive human
cervical cancer cell line containing integrated HPV18 DNA; E6 and E7
are expressed from the viral endogenous LCR and HPV18 E2 is not
expressed. The ﬁnding that E2 coimmunoprecipitated with both
EP400 and TIP60 suggests that E2 interacts with the TIP60 complex,
although we did not determine whether E2's interactions with EP400
and TIP60 are direct or indirect, nor whether a single complex contains
all three proteins.
TIP60 contributes to the repression of the HPV18 LCR
Several components of the TIP60 complex (EP400, Brd8, EPC1
and GAS41) were hits in our previous siRNA screen that identiﬁed
genes involved in E2-mediated repression of the HPV18 LCR
(Smith et al., 2010). The TIP60 histone acetyltransferase protein
was not identiﬁed as a repressor in the primary screen, which
utilized the Dharmacon siGENOME SMARTpool library (primary
screen data available via PubChem BioAssay AID: 624099). To test
Fig. 2. The EP400 fragments F1, F2, F4 and the SANT domain co-immunoprecipitate with BPV1 E2. (A) Schematic representation of the EP400 fragments relative to its
identiﬁed domains (Park et al., 2010). (B) C33A cells were transfected with expression plasmids for the FLAG-tagged EP400 fragments (F1–F6 and SANT domain of F4). 48 h
Post-transfection, cells were harvested, total proteins separated by SDS-PAGE and visualized by immunoblot analysis using antibodies against FLAG (detection of EP400
fragments) and actin. (C) C33A cells were transfected with expression plasmids for HA-tagged BPV1 E2, FLAG-tagged EP400 fragments, or the corresponding parental
plasmids. 48 h Post-transfection, cells were harvested and proteins immunoprecipitated with an antibody against HA. Total cellular proteins (Input) and bound proteins (IP:
HA) were separated by SDS-PAGE and visualized by immunoblot analysis using antibodies against HA (detection of BPV1 E2), FLAG (EP400 fragments) and actin. (D) The
same experiment as described above in C was performed, except that only the FLAG-tagged F1, F4 or SANT domain of EP400 was co-transfected with HA-tagged BPV1 E2.
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whether the TIP60 protein is a repressor of the HPV LCR that was
not detected in the primary screen, we tested the TIP60 siRNA
duplexes individually. Each duplex was transfected into C33A cells
that stably express an HPV18 LCR luciferase reporter as well as
HPV16E2 (C33A/16E2/18LCR), which effectively represses lucifer-
ase expression from the LCR. Non-targeting siRNA (siC#1) was
included as a negative control and siRNA duplexes targeting
HPV16 E2 and SMCX were included as positive controls. The
impact of these siRNA duplexes on luciferase expression in these
cells was established in our previous study (Smith et al., 2010).
As expected, knockdown of HPV16 E2 resulted in a signiﬁcant
increase in luciferase, indicating an alleviation of repression of the
HPV18 LCR. Luciferase levels also increased following SMCX
knockdown. When compared to the siC#1-transfected cells, each
of the four siRNA duplexes targeting TIP60 relieved E2-mediated
repression of the LCR, although the extent varied (Fig. 4A). Knock-
down of HPV16 E2 and TIP60 protein levels was validated by
western blot analysis (Fig. 4B).
EP400 and TIP60 have similar effects on E2-mediated transcriptional
repression of the HPV-18 LCR
Since EP400 and TIP60 are each components of the TIP60 histone
acetyltransferase complex (Doyon and Cote, 2004) and each contri-
butes to transcriptional repression of the HPV18 LCR, we next asked
whether they contribute in concert or individually to E2 regulation
of the LCR. To answer this question, C33A/16E2/18LCR cells were
transfected with a non-targeting siRNA duplex (siC#1) or siRNAs
directed at HPV16 E2, Brd4, EP400, TIP60 or EPC1 (Fig. 5). EPC1 is
another component of the TIP60 complex previously implicated in
contributing to E2-mediated regulation of the LCR. As expected, the
greatest increase in luciferase activity was observed when HPV16 E2
was depleted. In our previous study, we showed that depletion of both
Brd4 and EP400 resulted in an additive relief of E2-mediated repres-
sion (Smith et al., 2010). Co-transfection of the siRNA duplexes
targeting TIP60 and EP400 resulted in an increase in luciferase activity
comparable to that observed following the knockdown of TIP60 alone.
Similar ﬁndings were obtained when EPC1 was depleted in combina-
tion with either EP400 or TIP60. These data indicate that depletion of
the individual components of the TIP60 complex do not have additive
or synergistic effects on the relief of repression of the HPV18 LCR,
supporting the hypothesis that the TIP60 complex as a whole
contributes to E2 regulation of E6 and E7 expression.
Other members of the JARID1 family of histone demethylases do not
contribute to E2-mediated transcriptional repression of the HPV18
LCR in cervical cancer cells
SMCX is a member of the JARID1 family of histone demethylases,
which includes three other members: SMCY/JARID1D/KDM5D,
Fig. 3. BPV1 E2 co-immunoprecipitates with TIP60. C33A (A) or HeLa (B) cells were
transfected with expression plasmids for HA-tagged TIP60, FLAG-tagged F4 frag-
ment of EP400 fragment, dual HA- and FLAG-tagged BPV1 E2 or the corresponding
parental plasmids. 48 h post-transfection, cells were harvested and proteins
immunoprecipitated with an antibody against FLAG. Total cellular proteins (Input)
and bound proteins (IP:FLAG) were separated by SDS-PAGE and visualized by
immunoblot analysis using antibodies against HA (detection of BPV1 E2 and TIP60),
FLAG (F4 fragment of EP400 and BPV1 E2) and actin. Anti-Brd4 antibodies were
used to detect Brd4 as a positive control for an E2 interacting protein in HeLa cells.
Fig. 4. Depletion of TIP60 increases activity of the HPV-18 LCR. C33A/16E2/18LCR
cells were reverse transfected with non-targeting control siRNA (siC#1) or siRNA
duplexes targeting HPV-16 E2, SMCX or TIP60. At 72 h post-transfection, lysates
were harvested. Luciferase levels and total protein were quantitated. (A) Graph
represents the relative luciferase units (RLU) normalized to protein extract
concentration (RLU/[Protein]). (B) Western blots indicate depletion of HPV16 E2
and TIP60 proteins, as well as actin protein levels.
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Rbp2/JARID1A/KDM5A and Plu1/JARID1B/KDM5B. None of these
three genes scored as hits in our genome-wide siRNA screen (Smith
et al., 2010). The gene encoding SMCY is located on the Y chromo-
some and its expression is limited to the testes. Therefore although
SMCY is not expressed in C33A cells, the siRNAs targeting SMCY
were included as negative controls. By qPCR we determined that
Plu1, but not Rbp2 was expressed in the C33A cells, therefore Rbp2
could not be contributing to E2-mediated repression in C33A cells.
To determine whether Plu1 was a false negative in our screen and
might also contribute to E2-mediated repression of the HPV LCR, we
tested the individual siRNA duplexes for each of the JARID1 family
of histone demethylases in C33A/16E2/18LCR cells. As shown in
Fig. 6A, siRNA directed at either 16E2 or Brd4 signiﬁcantly increased
luciferase levels indicating a relief of E2-mediated repression of
the HPV18 LCR. Similarly, siRNAs directed against SMCX relieved
E2-mediated repression, most notably observed with the SMCX-02
and -04 siRNAs. In contrast, no change in luciferase levels was
observed in cells transfected with any of the siRNAs against Plu1,
SMCY or Rbp2. We therefore conclude that E2-mediated repression
speciﬁcally involves SMCX and not other members of the JARID1
family of histone demethylases. Depletion of SMCX and PLU1
transcripts by the individual siRNAs were quantitated by qPCR
and are shown in Fig. 6B normalized to β-actin transcript levels.
Histone H3 trimethylation at lysine 4 is reduced at the HPV18 LCR
in an E2- and SMCX-dependent manner
If SMCX contributes to E2-mediated repression of the LCR by
altering the methylation status of histone H3 lysine 4 there, we
would predict that the loss of E2 from HPV-positive cells would
eliminate the recruitment of SMCX to the LCR and alter chromatin
modiﬁcations at that site. To test this hypothesis, we ﬁrst char-
acterized E2 binding to the endogenous HPV18 LCR in HeLa cells by
chromatin immunoprecipitation (ChIP). For these experiments, we
utilized a HeLa cell line that had been engineered to additionally
express HPV16 E6 and E7 from retroviral promoters, which are not
Fig. 5. Combinatorial siRNA transfections reveal that members of the TIP60
complex act together in contributing to E2-mediated repression. C33A/16E2/
18LCR cells were transfected with the indicated siRNA duplexes alone or in
combination at a ﬁnal concentration of 10 nM/duplex. At 72 h post-transfection,
lysates were harvested. Luciferase levels and total protein were quantitated. The
graph represents RLU/[protein]. Experiments were performed in triplicate, with
each bar representing the average7SD.
Fig. 6. E2-mediated transcriptional repression of the HPV18 LCR in cervical cancer cells does not require other JARID1 family proteins. C33A/16E2/18LCR c1 cells were
transfected with the indicated siRNAs at a ﬁnal concentration of 20 nM. (A) Cell extracts were harvested 72 h post-transfection to determine RLU and total protein levels.
Experiments were performed in triplicate, with each bar representing the average7SD. (B) SMCX and PLU1 transcript levels were quantitated by qPCR in cells transfected
with the indicated siRNAs. The graph displays the relative mRNA levels normalized to β-actin transcript levels.
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subject to E2 repression (Psyrri et al., 2004). We further introduced
into these cells either a vector encoding BPV1 HA–FLAG–E2 or the
empty parental plasmid (Smith et al., 2010). By ChIP using anti-HA
antibodies, we were able to detect E2 bound at the HPV18 LCR
where four E2 binding sites are located but not over a region of the
L1 gene devoid of any E2 binding sites (Fig. 7).
To determine the potential effects of the E2–SMCX interaction,
we next examined the methylation status of histone H3 lysine 4 at
two regions of the HPV genome in the presence and absence of E2.
Trimethylated histone H3 lysine 4 (H3K4me3) is one of the marks
of transcriptionally active chromatin. In part through its ability to
demethylate tri- and di-methylated lysine 4 of histone H3, SMCX
functions as a transcriptional repressor (Iwase et al., 2007;
Tahiliani et al., 2007). ChIPs were performed examining the LCR
and the L1 region of the integrated HPV18 DNA sequences using
antibodies speciﬁc to total histone H3, H3K4me3, H3K4me2 or
H3K4me1 in HeLa/16E6/16E7/BE2 compared to HeLa/16E6/16E7/
pOZN cells. The amount of DNA corresponding to the HPV18 LCR,
L1 region or the β-actin promoter region was determined by qPCR.
Results are expressed as the amount of the HPV18 LCR associated
with a histone or modiﬁed histone relative to the amount of the
β-actin promoter associated with the same histone and are the
average of three independent experiments. Whereas the amount
of total H3 in association with the HPV18 LCR E6/E7 promoter was
similar in HeLa cells with or without E2; there was a signiﬁcant,
greater than 10-fold decrease in the amount of H3K4me3 asso-
ciated with the HPV18 LCR when E2 was present (Fig. 8A). There
was also a 3-fold decrease in H3K4me2 bound to the HPV18 LCR
promoter in the E2 expressing cells compared to the control
HeLa/16E6/16E7/pOZN cells. H3K4me1 was not affected by E2.
In contrast, the analysis of H3K4 modiﬁcations in the L1 ORF
showed minimal difference in the presence or absence of E2
(Fig. 8B), indicating that the E2-dependent decrease in H3K4me3
and H3K4me2 at the HPV18 LCR was speciﬁc to the LCR E6/E7
promoter. We note that due to the lack of antibodies suitable to
ChIP SMCX, we were unable to examine whether or not SMCX
itself was at the LCR.
To determine whether the decreased H3K4me3 and H3K4me2
at the HPV18 E6/E7 LCR were dependent upon SMCX, we
performed similar ChIP experiments in cells depleted of SMCX
by siRNA knockdown. Compared to non-targeting siRNA-treated
cells (siC#1), the knockdown of SMCX in the E2-expressing HeLa/
16E6/16E7 cells led to increased H3K4me3, H3K4me2 and
H3K4me1 at the HPV18 E6/E7 promoter (Fig. 8C, white bars versus
light black bars). Similar increases in H3K4me3 and H3K4me2
were observed in the cells transfected with BPV1 E2 siRNA (Fig. 8C,
gray bars). In contrast, the methylation levels of H3K4 at the
HPV18 E6/E7 promoter in either siC#1 siRNA- or in SMCX siRNA-
transfected HeLa/16E6/16E7/pOZN cells did not affect H3K4me3,
H3K4me2 or H3K4me1 levels (Fig. 8D, white bars versus black
bars). Together, these results indicate that SMCX is responsible
for the decreased methylation of H3K4 at the HPV18 LCR in an
E2-dependent manner.
To determine if the SMCX- and E2-dependent changes in the
methylation status of H3K4 described above are speciﬁc to the
HPV18 LCR, we performed the same siRNA knock down/ChIP
experiments examining the L1 ORF since E2 does not affect
transcription from this region of the HPV18 genome. Knockdown
of BPV1 E2 did not impact the methylation states of H3K4 in the L1
ORF (Fig. 8E, white bars versus gray bars). While the depletion of
SMCX did increase L1-associated H3K4me3, H3K4me2 and
H3K4me1 compared to the siC#1-transfected cells (Fig. 8E, white
bars versus black bars), the change was modest (2.5-fold) com-
pared to the over 10-fold increase of HPV18 E6/E7 promoter-
associated H3K4 in HeLa/16E6/16E7/BE2 cells (Fig. 8C). The knock-
down of SMCX also increased H3K4 methylation at the HPV18 L1
ORF in HeLa/16E6/16E7/pOZN cells (Fig. 8F), further supporting the
interpretation that any SMCX-mediated effect of H3K4 methyla-
tion at the L1 ORF was not mediated by E2.
These data indicate that there was a speciﬁc E2- and SMCX-
dependent decrease in the methylation of H3K4me3 and
H3K4me2 at the HPV18 LCR (Fig. 8). Based on this observation
and evidence indicating that speciﬁc nucleosome structures along
the HPV16 and HPV18 LCRs contribute to E6 and E7 expression
(Stunkel and Bernard, 1999), we hypothesize that E2 recruits SMCX
to the HPV18 LCR to maintain a transcriptionally inactive promo-
ter, thus decreasing E6 and E7 expression. Using siRNA knockdown
and ChIP experiments, we demonstrate a speciﬁc E2- and SMCX-
dependent decrease in the methylation of H3K4me3 and
H3K4me2 at the HPV18 LCR.
Fig. 7. BPV1 E2 is present at the HPV18 LCR in HeLa cells. (A) Map of the HPV18 viral genome in HeLa cells, with the DNA sequences that were ampliﬁed via PCR indicated.
DNA sequences encompassing the transcription start site in the HPV18 LCR (B) or L1 ORF (C) and associated with BPV1 E2 were quantitated in HeLa/16E6/16E7/BE2 or HeLa/
16E6/16E7/pOZN cells after ChIP using antibodies against the HA-tag on BPV1 E2 via qPCR. The fold change displayed on the y-axis represents data normalized to the β-actin
transcriptional start site, with each bar representing the average of three experiments7SD. Asterisks represent the level of signiﬁcance (np-valuer0.05 and
nnp-valuer0.005), as determined via unpaired t-tests.
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Discussion
In this study, we have extended our analysis of the cellular
genes and pathways that are engaged by the papillomavirus E2
regulatory protein in mediating its transcriptional repression
function. This E2 mediated repression function is important during
papillomavirus replication in the negative regulation of the long
control region (LCR) promoter that drives E6 and E7 expression.
For the high risk HPVs associated with human cancer, E6 and E7
are responsible for cellular transformation. Thus, through its
repression of E6 and E7, E2 effectively functions as a tumor
suppressor gene in HPV-positive cancers. In HPV-associated can-
cers, the expression of E2 is frequently lost following integration of
the HPV genome into cellular DNA in a manner that disrupts the
integrity of the E2 ORF (Howley et al., 2013). The re-expression of
E2 in HPV positive cancers causes cellular senescence due to the
silencing of the E6 and E7 oncoproteins (Goodwin and DiMaio,
2000; Wells et al., 2000).
Our previous unbiased, genome-wide siRNA screen demon-
strated that 96 cellular genes are involved in repression of the HPV
LCR promoter (Smith et al., 2010). Although some of these genes
could repress the HPV LCR in the absence of E2, most could not.
From this study came the realization that E6/E7 repression occurs
through multiple E2-dependent and -independent mechanisms.
Three of the strongest hits in the screen were Brd4, EP400 and
SMCX, and each of these proteins contributes to E2-mediated
repression in an independent and additive fashion. Brd4, a cellular
protein previously implicated in E2-mediated repression of the
LCR (Wu et al., 2006), was the focus of our initial follow-up
studies. In addition, we showed that E2 could bind SMCX and
EP400. These binding partners of E2 are notable since both have
the potential to modify chromatin – either directly, in the case
of SMCX, or in association with the TIP60 complex, as for
EP400. The goal of the current study was to further investigate
how chromatin-modifying enzymes or complexes contribute to
E2-mediated repression of the HPV LCR.
Virus-mediated control of chromatin modiﬁcation has been
established as an important regulatory mechanism. Many viruses
target TIP60, often through a protein–protein interaction. Indeed
TIP60 is named Tat interacting protein, 60 kDa based on its initial
identiﬁcation as a binding partner of HIV Tat (Kamine et al., 1996).
In general, TIP60 functions as a repressor of transcription, and
some virus interactions with TIP60 result in TIP60 inactivation,
often through degradation. In addition to HIV Tat, HCMV pUL27
(Reitsma et al., 2011), Adenovirus E1B55K and E4orf6 (Gupta et al.,
2013) and HPV16 and HPV18 E6 (Jha et al., 2010) have been
Fig. 8. E2 and SMCX contribute to a reduction in H3K4me3 at the HPV18 LCR. The amount of total H3, H34K4me3, H3K4me2 and H3K4me1 associated with the transcription
start site present in the HPV18 LCR (A) or HPV18 L1 ORF (B) was determined in HeLa/16E6/16E7/BE2 or HeLa/16E6/16E7/pOZN cells by ChIP. The fold change displayed on the
y-axis represents data normalized to the β-actin transcriptional start site, with each bar representing the average of three experiments7SD. HeLa/16E6/16E7/BE2 (C, E) or
HeLa/16E6/16E7/pOZN cells (D, F) were transfected with the indicated siRNAs (legend in C). 72 h Post-transfection, the amount of total H3, H34K4me3, H3K4me2 and
H3K4me1 associated with the HPV18 LCR (C, D) or L1 ORF (E, F) was determined by ChIP. The fold change displayed on the y-axis represents data normalized to the β-actin
transcriptional start site, with each bar representing the average of two experiments7the difference between them. Asterisks represent the level of signiﬁcance
(np-valuer0.05 and nnp-valuer0.005), as determined via unpaired t-tests.
J.A. Smith et al. / Virology 468-470 (2014) 311–321 317
reported to target TIP60 for proteasome-mediated degradation.
Consistent with its inactivation by a broad range of viruses, TIP60
and other members of its complex have recently been shown to
have anti-ﬂaviviral effects in mammalian cells (Yasunaga et al.,
2014). Thus TIP60 serves as a regulator of antiviral activity for
many diverse viruses. In contrast, TIP60 promotes progression of
some virus infections. KSHV LANA binds but does not degrade
TIP60 (Shamay et al., 2012), and it appears that a variety of herpses
viruses exhibit impaired replication when TIP60 is depleted
(Li et al., 2011). It seems that TIP60 could have context-
dependent positive or negative effects on viral functions and that
viruses could redirect, not just inactivate, its functions to promote
virus replication.
Although our previous study focused on EP400, one component
of the TIP60 histone complex, other components including Brd8
and EPC1, also scored in our assay and suggested a role for the
complex as a whole (Smith et al., 2010). We therefore wished to
determine whether other components of the TRRAP/TIP60 com-
plex also contributed to repression or whether EP400 contributes
uniquely. Subsequent to our publication, the TIP60 protein was
shown to function in the negative regulation of the high risk HPV
LCR E6/E7 promoter, although in a manner that was independent
of E2 (Jha et al., 2010). Since TIP60 had not scored as a hit in our
whole genome siRNA screen, we examined each of the four siRNA
duplexes in the TIP60 SMARTpool individually to determine their
effects on E2-mediated repression. Although the TIP60 SMARTpool
itself did not relieve E2-mediated repression of the HPV18 LCR in
the initial screen, each of the individual siRNAs did when tested
individually (Fig. 4). Combination experiments with siRNAs target-
ing TIP60, EP400 and EPC1 did not provide additive relief of E2
repression compared to the knockdown of individual TIP60 com-
plex components. Thus, depletion of any one subunit of the TIP60
histone acetyltransferase complex may be sufﬁcient to override
E2-driven repression.
In addition to E2's ability to bind EP400, we demonstrate co-
immunoprecipitation between E2 and TIP60, and mapped the
binding regions on EP400 for E2 to the same regions that have
been previously mapped for the binding of TIP60 to EP400 (Park
et al., 2010). Although our data indicate that E2 engages the TIP60
complex, we have not identiﬁed which speciﬁc protein (or
proteins) E2 binds within the complex. Nonetheless, our results
validate a role for the TIP60 complex in E2-mediated repression
of the high risk HPV LCR. Our previous study showed an
E2-dependence for both EP400 and EPC in E2-mediated repression
of E6/E7 expression (Smith et al., 2010). We note however that an
E2-independent role for TIP60 repression of the LCR has been
established and shown to occur in a Brd4-dependent manner (Jha
et al., 2010).
To our knowledge, our study describes the ﬁrst example of a
virus-encoded protein that binds to and/or alters the target of
SMCX. Several viruses modulate the function of other lysine
demethylases in the KDM family. For example herpes simplex
virus and varicella zoster virus recruit the lysine-speciﬁc demethy-
lase 1 (LSD1/KDM1A) to the viral immediate-early promoter,
where it enables viral lytic gene expression (Liang et al., 2009),
and consistent with this an inhibition of LSD1 blocks HSV gene
expression (Liang et al., 2013). The latency-associated nuclear
antigen (LANA) encoded by Kaposi's Sarcoma herpesvirus (KSHV)
binds to KDM3A, and the KSHV K-bZIP binds to KDM4A (Chang et
al., 2011; Kim et al., 2013), and one report suggests that KDM6B
overexpression results from Epstein-Barr virus infection (Anderton
et al., 2011).
Our data examining SMCX and other members of the JARID1
family of histone demethylases (Rbp2, Plu1 and SMCY) indicate that
SMCX is the sole member that contributes to E2-mediated tran-
scriptional repression. As demonstrated in the ChIP experiments,
there is a clear decrease in the level of trimethylated H3K4 at the
HPV18 LCR in the presence of E2. We go on to show that this
decrease in H3K4me3 is speciﬁc to the HPV18 LCR and requires
both SMCX and the papillomavirus E2 protein. We hypothesize that
E2, through its ability to bind to the E2 binding sites within the
HPV18 LCR, recruits additional cellular proteins, including SMCX.
SMCX then demethylates H3K4, thus contributing to decreased
transcription of the papillomavirus E6 and E7 oncogenes through
this chromatin modiﬁcation.
The ability of the papillomavirus E2 protein to regulate expres-
sion of E6 and E7 from the LCR is complex, involving multiple
cellular proteins. These proteins, including Brd4, SMCX and the
TRAAP/TIP60 complex, contribute to repression through distinct
mechanisms and their activities are required in order to maximize/
to ensure maximal E2-mediated repression. The chromatin micro-
environment surrounding the LCR is key since all of these proteins
modulate chromatin modiﬁcations. E2 plays a central role, as it is
able to recruit cellular proteins to the E6 and E7 promoter. Thus,
the elimination of E2 during carcinogenesis disrupts the ability of
Brd4, SMCX and members of the TIP60 complex to inﬂuence
expression from the LCR, resulting in increased expression of the
papillomavirus oncogenes and HPV-associated cancer.
Materials and methods
Cell culture and cell lines
C33A and HeLa cells were maintained as monolayer cultures in
high-glucose Dulbecco's modiﬁed Eagle's medium (hgDMEM)
with 10% fetal bovine serum (FBS), 50 units/ml penicillin G and
50 μg/ml streptomycin sulfate (P/S). HeLa/sen2 RVY16E6
LXSN16E7 #21 cells (HeLa/16E6/16E7) were graciously provided
by Dan DiMaio (Psyrri et al., 2004) and maintained as monolayer
cultures in hgDMEM with 10% FBS, 10 mM HEPES (pH 7.2), 0.5 mg/
ml G418, 125 μg/ml hygromycin B and P/S. To stably transduce
HeLa/16E6/16E7 cells, pOZN or pOZN–HPV16E2 (p6072) were
packaged following standard retrovirus production protocols and
cells were infected with clariﬁed supernatant of packaging cells
(Ogawa et al., 2002; You et al., 2004; Zheng et al., 2009). The
resulting cell lines are referred to as HeLa/16E6/16E7/pOZN and
HeLa/16E6/16E7/16E2. C33A cells stably transduced with pOZN–
HPV16E2 and HPV18LCR–luciferase (C33A/16E2/18LCR) have been
previously described (Smith et al., 2010).
Expression plasmids
The following plasmids have been described: pcDVL (p1151);
codon-optimized BPV1 E2 (C59 E2kz, p2450), pOZN–HA–BPV1E2
(p6094), pOZN–HA–HPV16E2 (p6093), pCMV–HPV16E2 (p3766),
pDEST–HA–BPV1E2 (p6244), pDEST–HA–HPV16E2 (p6245), pOZ–
N-HA–BPV–1 E2 (p6094), pOZ–N-FLAG–HA–BPV-1 E2 (p5066),
pOZ–N-HA–BPV-1 E2R37A (p6752), pOZ–N-HA–BPV-1 E2I73A
(p6753), and pOZ–N-HA–BPV-1 E2R37AI73A (p6754) (Schweiger
et al., 2006; You et al., 2004; Zheng et al., 2009). pDEST–FLAG–
SMCX and pDEST–HA–SMCX were graciously provided by Shigeki
Iwase and Yang Shi (Iwase et al., 2007). pCMVb–FLAG–EP400 has
been previously described (Fuchs et al., 2001). Plasmids derived
from the C-βS mammalian expression vector, containing FLAG-
tagged EP400 Fragments F1–F6 and the SANT domain as well as
the FLAG-tagged EP400 full-length plasmid were kindly provided
by Robert Roeder (Park et al., 2010). pcDNA–HA–TIP60 was
graciously provided by Brendan Price (Sun et al., 2009).
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siRNAs and transfections
siGENOME siRNA duplexes were purchased from Dharmacon/
Thermo Fisher Scientiﬁc (Nontargeting siControl #1 (siC#1):
D-001210-01; siGLO RED: D-001630-02; Brd4-05: D-004937-05;
EP400-03: D021272-03; EPC1-01: D006376-01; TIP60 set of
4 duplexes: MQ-006301-01; SMCX set of 4 duplexes: MQ-
010097-00; PLU1 set of 4 duplexes: MQ009899-00; RBP2 set of
4 duplexes: MQ003297-01; SMCY set of 4 duplexes: MQ-010820-
00; and custom synthesis of siRNA duplex targeting HPV16E2
(16E2#2): GUUUAAAGAUGAUGCAGAA). Cells were transfected
with siRNAs using DharmaFECT1 (HeLa cells) or DharmaFECT2
(C33A cells) following slight modiﬁcations to the manufacturer’s
instructions (Dharmacon). Brieﬂy, siRNAs were diluted in 1
siRNA buffer (Dharmacon), then complexed with DharmaFECT in
OptiMEM in the wells/plates used for the experiment. Cells that
had been depleted of antibiotics for one day were seeded on top
of the siRNA/DharmaFECT mixture at densities to result in near
conﬂuent monolayers at the end of the experiment. After 24 h
incubation at 37 1C, media was removed and cells were incubated
in hgDMEM plus 10% FCS for an additional 48 h.
Quantitation of luciferase activity
At the indicated times post-transfection, cells were washed,
scraped and lysed in 1 Reporter Lysis Buffer (Promega). Clariﬁed
lysates were analyzed for luciferase activity using the Promega
Luciferase Assay System and a luminometer. Lysate protein con-
centrations were determined using a protein assay kit (BCA
protein assay kit, Thermo Fischer Scientiﬁc). All experiments were
performed in triplicate.
Analysis of protein expression
Equivalent amounts of protein were suspended in protein
sample buffer (50 mM Tris pH6.8, 5% SDS, 10% glycerol, 5%
β-mercaptoethanol, 25 mM NaF, 1 mM Na3VO4, 5 mM β-glycero-
phosphate, 1 mM PMSF, 50 mM Leupeptin, 100 mM Pepstatin A),
resolved by electrophoresis in Bis–Tris polyacrylamide gels and
transferred to polyvinylidene ﬂuoride membranes by electroblot-
ting. Membranes were blocked in TNET (10 mM Tris pH 7.5, 50 mM
NaCl, 2.5 mM EDTA pH 8.0, 0.1% Tween) supplemented with 5%
nonfat dry milk. Primary antibodies used in these experiments
were against: HA (#12013819001, Roche), FLAG (F3165, Sigma),
SMCX (NB100-55328, Novus Biologicals), EP400 (A300-541A,
Bethyl Laboratories), Brd4 (Schweiger et al., 2006), TIP60
(sc-16623, Santa Cruz Biotechnology) and actin (MAB1501, Milli-
pore). Bound antibodies were detected with horseradish perox-
idase conjugated anti-rabbit or anti-mouse secondary antibodies.
For detection of actin, membranes were incubated with an Alexa-
Fluor 680 conjugated goat anti-mouse IgG secondary antibody
(Molecular Probes/Invitrogen) and labeled proteins visualized
using a LI-COR Odyssey Infrared Imaging System.
Quantitative RT-PCR
Total RNA was isolated from cell pellets using the NucleoSpin
RNA II kit (Clontech) following manufacturer's instructions. The
concentration of each sample was determined by UV spectro-
photometry (Nanodrop). To remove residual DNA contamination,
puriﬁed RNAs were treated with DNase using the Turbo DNA-free
kit (Ambion), which includes a DNase inactivation and removal
step. Equal amounts of RNA were reverse transcribed using the
High Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems). Quantitative real-time PCR was performed in an Applied
Biosystems ABI 7500 Fast Sequence Detection System using
TaqMan Fast Universal PCR Master Mix (Applied Biosystems),
oligonucleotide primers and TaqMan dual-labeled probes
(50FAM, 30Black hole quencher or 50FAM, 30Iowa Black Quencher;
Integrated DNA Technologies). Real-time PCR assays to detect
cellular genes were ordered from Applied Biosystems/Life
Technologies and have assay ID numbers as follows: SMCX
(KDM5C): Hs01011846_m1; PLU1 (KDM5B): Hs00981910_m1;
actin: Hs01060665_g1.
Transient DNA transfections and immunoprecipitations
One day prior to transfection, cells were plated to result in
near-conﬂuent monolayers at the end of the experiment. Cells
were transfected with the indicated plasmids using a 3:1 FuGENE
(ml):DNA (mg) ratio according to the manufacturer's protocol
(Roche). At 48 h post-transfection, cells were washed with PBS,
and then lysed in 1 lysis buffer (PBS, 0.5% NP40, 1 BD protease
inhibitors, 1 mM DTT, 12.5 mM NaF, 1 mM Na3VO4, 12.5 mM
β-glycerophosphate). Cell lysates were then sonicated for 8 s at
35% intensity to shear nucleic acids and lysates were clariﬁed by
centrifugation. For immunoprecipitation experiments, anti-HA
(Sigma A2095) or anti-FLAG beads (Sigma A2220) were added to
lysates and incubated overnight at 4 1C. Beads and bound proteins
were washed 4 in 1 lysis buffer without DTT. Bound proteins
were removed by brieﬂy boiling beads in 1 sample buffer.
Proteins were separated and analyzed as described above.
Chromatin immunoprecipitations (ChIP)
At the time of harvest, cells were washed once with PBS, then
incubated with 500 mM DTBP diluted in PBS for 30 min to cross-
link DNA and protein. The reaction was quenched by adding
100 mM Tris/HCl (pH 8.0) and 150 mM NaCl, followed by 5 min
incubation. Cells were washed with PBS, incubated for 10 min with
1% formaldehyde, followed by the addition of 100 mM glycine for
an additional 10 min. Cells were lysed with cell lysis buffer (5 mM
PIPES (pH 8.0), 85 mM KCl, 0.5% Nonidet P-40 and 1 BD protease
inhibitors), pelleted and resuspended with buffer A (50 mM
HEPES/KOH (pH 7.6), 500 mM NaCl, 1% Triton X100, 0.1% sodium
deoxycholate, 1 mM EDTA). The mixture was then sonicated
520 s resulting in 200–500 base pair fragments, pelleted and
resuspended in buffer A. The supernatant was pre-cleared
with protein A/G-agarose (200 μL Protein A-agarose (PIERCE),
200 μL Protein G-agarose (PIERCE), 240 μL buffer A, 80 μL BSA
(10 mg/mL), 80 μL sheared salmon sperm DNA (10 mg/mL), 0.1%
NaN3), diluted with buffer A and incubated with 5 μg of the
appropriate antibody overnight at 4 1C. Antibodies used were:
Total H3 (ab1791, Abcam); H3K4me3 (ab1012, Abcam); H3K4me2
(07-030, Millipore); H3K4me1 (ab8895, Abcam); HA (ab9110,
Abcam); rabbit IgG (ab46540, Abcam); and mouse IgG (ab37355,
Abcam). Antibodies and bound protein were captured with protein
A/G-agarose. The beads were washed with buffer A, buffer B
(50 mM HEPES/KOH (pH 7.6), 0.3 M LiCl, 1 mM EDTA, 0.5% NP-
40, 0.7% sodium deoxycholate) and TE (1 mM EDTA, 10 mM Tris
(pH 8.0), 12.5 mM β-glycerophosphate, 12.5 mM NaF, 1 mM
Na3VO4, 1 BD protease inhibitors) then the protein/DNA com-
plexes were removed with elution buffer (50 mM NaHCO3, 1% SDS,
10 mM DTT, 0.3% sheared salmon sperm DNA, 10 mM EDTA and
0.2 M NaCl). Crosslinks were reversed by incubation at 65 1C,
followed by RNA and protein digestions with RNase A and
proteinase K respectively. DNA was puriﬁed with the Qiagen PCR
puriﬁcation kit according to manufacturer's instructions for qPCR
quantiﬁcation (Qiagen). Speciﬁc sequences present in equal
volumes of input or immunoprecipitated DNA were quantiﬁed by
real-time PCR performed in an Applied Biosystems ABI 7500
Fast Sequence Detection System using TaqMan Fast Universal
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PCR Master Mix (Applied Biosystems). Custom designed HPV18
and beta-actin promoter TaqMan assays (Integrated DNA Technol-
ogies) had sequences as follows: HPV18 L1 Forward primer
50 AGCCTTTAGGTGTTGGCCTTAGT 30, TaqMan probe 50 6-FAM-
ACACTGAAAGTTCCCATGCCGCCA-Iowa Black quencher 30, Reverse
primer 50 TTGTCCCTAACGTCCTCAGAAAC 30. HPV18 LCR Forward
primer 50 GGTTGGGCAGCACATACTATACTTT 30, TaqMan probe
50 6-FAM-CGGTCGGGACCGAAAACGGTG-Iowa Black quencher 30,
Reverse primer 50 CATGGTATTGTGGTGTGTTTCTCACAT 30. Beta-
actin promoter Forward primer 50 CGCACAGTGCAGCATTTTTT 30,
TaqMan probe 50 6-FAM-ACCCCCTCTCCCCTCCTTTTGCG 30, Reverse
primer 50 CTCCCTCCTCCTCTTCCTCAA 30. Unpaired t-tests were
performed on all ChIP experiments to calculate two-tailed P
values, with asterisks in the ﬁgures representing the level of
signiﬁcance (nr0.05 and nnr0.005).
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